Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

To confirm the bearish trend, PFE has been trading below its 50-day moving average since October 2024, experiencing some fluctuations. The stock is trading below its 200-day moving average since ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Pfizer (PFE) stock is lower in Tuesday's session even ... pipeline," said Pfizer CEO Dr. Albert Bourla in a statement. "Our performance through the first three quarters of the year is the result ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.